VI Partners Venture Fund (2026)

About VI Partners Venture Fund (2026)

Zug-based VI Partners marked its 25th anniversary with the first close of a new venture fund, targeting CHF 150M. Invests in early-stage technology and healthcare companies.

Investment Focus

Location / RegionSwitzerland

Funding StageSeed

Industry Focus

Ai Ml

Biotech

Digital Health

Enterprise Software

Fintech

Manufacturing

Med Tech

Investor Signals Profile

active

Sweet Spot

Swiss deep tech or biotech founder seeking active Series A lead

Swiss deep tech

biotech/medtech

B2B SaaS

ETH Zurich spinouts

Series A lead

Bullish Signals

CHF 150M new fund, first close Jan 2026external

72 investments, 5 unicorns, 25yr track recordexternal

Portfolio: JenaValve FDA approved Mar 2026external

Oculis EMA PRIME designation Mar 2026external

Strong founder NPS; repeat CEO backingexternal

Bullish on intelligent software, not SaaS-deadexternal

Digital twins in oncology — new thesis signalexternal

5 named CEOs publicly endorse Vi Partnersexternal

Contrarian Signals

Swiss-only focus limits deal universeexternal

Deep tech = longer time to liquidityexternal

Team page light on named senior GPsexternal

Founder Do's

Be Swiss-based or ETH-linked

Show deep tech or biotech differentiation

Seek lead investor at Series A

Expect board-level operational support

Bring long-term vision, not quick flip

Founder Don'ts

Don't expect passive capital only

Avoid non-Swiss/non-European focus

Don't skip clinical/technical validation

Key GPs & Partners

Julien Pache

Partner, Technology

tech-focusednew addition 2026

Unlock Investor Signals

$29/month for full signal access. Cancel anytime.

View Plans Browse all Signal Profiles →

Fund Overview

Fund Size€161M

Saves0

Website

Key People

VI Partners

Julien PachePartner, Technology